Intravenous cyclosporine-rifampin interaction in a pediatric bone marrow transplant recipient

Pharmacotherapy
Elyse J Zelunka

Abstract

A 10-year-old girl with chronic myelogenous leukemia began receiving cyclosporine the day before bone marrow transplant surgery Three days after the transplant, she developed fever and neutropenia due to a Staphylococcus aureus bacteremia. Despite treatment with various antibiotics, the patient's fever persisted over the next 4 days. Intravenous rifampin was added to her antibiotic regimen of piperacillin, tobramycin, cloxacillin, and amphotericin. On day 12, the patient's blood cultures were negative and her fever had resolved; rifampin was discontinued. On day 16, the patient engrafted; she subsequently developed a grade II graft-versus-host disease of the skin and gastrointestinal tract, which responded to methylprednisolone. Her cyclosporine blood levels, which had been subtherapeutic since day 5 despite increasing intravenous dosages, were within the therapeutic range on day 21, and she was discharged 12 days later. To our knowledge, this is the first documented case of an intravenous cyclosporine-rifampin interaction that resulted in subtherapeutic cyclosporine concentrations in a child receiving a bone marrow transplant who subsequently developed acute graft-versus-host disease.

References

Nov 1, 1992·The Journal of Clinical Investigation·J C KolarsP B Watkins
Sep 15, 1984·Lancet·N J DanielsR K Schachter
Feb 1, 1995·The Annals of Pharmacotherapy·E Zylber-Katz
Jul 1, 1993·Transplantation·B PeschkeE H Scheuermann
May 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·R M PlemmonsR L Ward
Jul 29, 1998·The Annals of Pharmacotherapy·E L MichaletsE D Van Tassel
Jul 20, 1999·The Journal of Clinical Investigation·B GreinerH K Kroemer

❮ Previous
Next ❯

Citations

Feb 17, 2006·Annals of Clinical Microbiology and Antimicrobials·Jiezhong Chen, Kenneth Raymond
Mar 11, 2008·Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie·A GauchonJ-L Bernard
May 19, 2006·Medical Care·Jennifer Elston LafataMarianne Ulcickas Yood
Nov 13, 2002·Pharmacoepidemiology and Drug Safety
Feb 16, 2008·The American Journal of the Medical Sciences·Anne M BaciewiczTimothy H Self
Apr 25, 2007·Cancer Treatment Reviews·S HarmsenJ H M Schellens
Dec 18, 2013·British Journal of Clinical Pharmacology·Spencer Y LingRobert T Foster
Nov 28, 2018·Expert Opinion on Drug Metabolism & Toxicology·Ana PejčićMiloš Milosavljević
Aug 23, 2007·Joint Commission Journal on Quality and Patient Safety·Jennifer Elston LafataMarianne Ulcickas Yood

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

CRISPR & Staphylococcus

CRISPR-Cas system enables the editing of genes to create or correct mutations. Staphylococci are associated with life-threatening infections in hospitals, as well as the community. Here is the latest research on how CRISPR-Cas system can be used for treatment of Staphylococcal infections.